TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Skyrizi (Risankizumab)

Skyrizi / Risankizumab. The subcutaneous products on this page are mainly used for plaque psoriasis and psoriatic arthritis.

PMDAproduct-level source2026-09label updated2026-10-05site verified
スキリージ皮下注55mg/75mg/150mg シリンジ・150mgペン · 150 mg / 1 mL pen
Japanese product photo · 150 mg / 1 mL pen · スキリージ.jp / アッヴィ
Main useThe subcutaneous products on this page are mainly used for plaque psoriasis and psoriatic arthritis.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
スキリージ皮下注55mg/75mg/150mg シリンジ・150mgペン
Brand
Skyrizi
Generic name
Risankizumab
Japanese generic name
リサンキズマブ
Chinese name
利生奇珠单抗
Marketing authorization holder
アッヴィ合同会社
Strengths
55 mg / 75 mg / 150 mg
Dosage form
SC syringe / pen
Therapeutic area
Immunology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Skyrizi is an IL-23-p19 antibody. This record covers Japanese 55/75/150 mg SC products, separate from IBD presentations.

Read source section ↗
02

Mechanism of action

Neutralizes IL-23 by binding its p19 subunit and reduces downstream inflammatory signaling.

Read source section ↗
03

Japanese indications & eligibility

Selected psoriasis/PsA variants and formulation-dependent palmoplantar pustulosis; pediatric 55 mg provisions differ.

Read source section ↗
04

Administration & dose differences

Usually doses at week 0, week 4 and every 12 weeks thereafter; pediatric dose is weight-based from age six.

Read source section ↗
05

Adverse effects & key risks

Watch serious infection, TB, hypersensitivity and injection reactions throughout the dosing interval.

Read source section ↗
06

Contraindications & special populations

Contraindicated in serious infection, active TB and ingredient hypersensitivity.

Read source section ↗
07

Drug interactions

Review live vaccines and other immunomodulators; self-injection requires training.

Read source section ↗
08

Assessment & monitoring

Assess TB/infection and monitor skin/joint response, handling and adverse symptoms.

Read source section ↗
09

Storage & handling

Refrigerate at 2–8°C, protect from light, do not freeze or shake; follow device-specific instructions.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.